Phil Rackliffe
General Manager, Allergy and Pediatrics
kaléo
Zealot for Improved Patient Outcomes
Phil Rackliffe has been disrupting the pharmaceutical and life science industries for more than 20 years. Ever a zealot for the patient, patient experience, and healthcare provider, Phil has launched more than 25 life science products in his pursuit to enable an improved healthcare outcome for all.
He began his career in management consulting with Ernst & Young and quickly transitioned into pharmaceutical sales with Pfizer. Phil was recognized as a leader amongst his peers turning around challenging business conditions by focusing on the outcome of the patients.
While completing his MBA, he moved to a career in the medical device industry with Boston Scientific. His ability to build strong advocates and focus on patient outcomes propelled him to the top-selling sales professional in the company which he parlayed into a corporate role. Phil used this opportunity to initiate and close three business development deals resulting in significant growth for the company enabling the delivery of a comprehensive suite of products and innovative solutions for the patient.
Next, Phil went to Baxter where he successfully led the commercialization and global launch of the first-to-world parenteral nutrition product for premature infants to the neonatology sector. During his tenure, he led multi-billion-dollar global businesses offering a suite of pharmaceutical, parenteral nutrition, compounding, and IV products. Patient experience remained core as Phil spent many weeks apart from his young family to facilitate key business development deals in pursuit of global growth.
Presently, Phil is General Manager of Allergy and Pediatrics at kaléo where he has been instrumental in driving growth and disruption within the epinephrine auto-injector market despite an entrenched competitor. He has steadfastly led teams to address significant patient needs in the U.S. and Canada with recently made public announcements. And, most recently he launched the first, and only, product for infants weighing under 33lbs within this space.
His quest for innovative healthcare solutions and an unwavering commitment to the patient are the driving force behind his continued disruption of the status quo.
